Indication

Target/marker/pathway

Summary

Licensing status

Publication and contact information

Cancer

Cancer

Tubulin

A mouse study suggests photodynamic therapy (PDT) with red light-activated prodrugs could help treat cancer with fewer side effects than existing chemotherapeutics. A prodrug composed of a tubulin-binding compound linked to a photosensitizing agent was designed such that free drug would be released upon exposure to red light. In a human breast cancer cell line, the prodrug plus red light increased apoptosis compared with the prodrug alone. In a mouse model for colon cancer, prodrug plus irradiation with red light decreased tumor growth compared with prodrug or vehicle alone, without causing observable toxicity. Future studies could include synthesizing and testing prodrugs of other classes of cancer drugs.

SciBX 6(20); doi:10.1038/scibx.2013.491
Published online May 23, 2013

Patent and licensing status unavailable

Bio, M. et al. J. Med. Chem.; published online April 30, 2013;
doi:10.1021/jm400139w
Contact:
Youngjae You, University of Oklahoma, Oklahoma City, Okla.
e-mail:
youngjae-you@ouhsc.edu